Company Overview
LeonaBio, Inc. operates as a clinical-stage biopharmaceutical company dedicated to the development of small molecules designed to restore neuronal health and slow the process of neurodegradation. The organization functions within the healthcare sector, specifically the biotechnology industry, a domain characterized by high capital requirements and significant uncertainty regarding the commercial success of early-stage product pipelines. The company's current scale is reflected in a market capitalization of $83.74M and an employee base of 26 individuals, with no reported annual revenue to date. These valuation and operational metrics indicate that LeonaBio is a micro-cap entity in a highly competitive therapeutic space, where value is derived primarily from the potential future commercialization of its pipeline assets, such as ATH-1105 for amyotrophic lateral sclerosis and ATH-1020 for other treatments, rather than current cash flow generation. The absence of significant revenue suggests the company is still in the research and development phase, which is typical for firms focused on restoring neuronal health before entering the market with approved therapies.
Financial Health
LeonaBio, Inc. reported a net income of $-37,723,000 and an EBITDA of $-38,295,000 over the trailing twelve-month period, while revenue figures are not available, indicating a complete absence of commercial sales. The substantial gap between revenue and net income, combined with the lack of revenue data, reveals a cost structure dominated by research and development expenses and general corporate overhead rather than cost of goods sold or operating costs associated with an established manufacturing base. The company's free cash flow stands at $-30,363,876, a metric that signifies a heavy consumption of cash reserves to fund ongoing clinical trials and operational expansion, thereby limiting immediate financial flexibility for external investments or acquisitions. All three margins—gross margin, operating margin, and profit margin—are reported at 0.0%, which indicates that the company has not yet generated enough revenue to cover its direct costs or operating expenses, resulting in zero profitability across all standard margin calculations. Regarding the balance sheet, the company holds $25.23M in cash against $912,000 in debt, creating a conservative leverage position despite a debt-to-equity ratio of 3.40, which reflects the accounting treatment of negative equity or specific capitalization structures common in biotech. The current ratio is listed at 9.70, a figure that suggests strong short-term liquidity relative to obligations, though this metric must be interpreted with caution in a pre-revenue environment where inventory levels are likely negligible. Return on Equity is -89.4% and Return on Assets is -42.2%, metrics that reveal management is currently burning capital to generate value for shareholders and assets rather than producing positive returns, a standard reality for clinical-stage firms but one that signals a high risk profile for capital preservation.
Valuation Assessment
LeonaBio, Inc. has a P/E Ratio (TTM) and Forward P/E listed as N/A due to negative earnings, a condition that implies these traditional valuation multiples are mathematically undefined and not applicable for assessing the company's current earnings trajectory. The price-to-book ratio is 1.32, which indicates that the market values the company at 32% above its net asset book value, suggesting investors are pricing in the future potential of the drug pipeline rather than the value of existing tangible assets. The price-to-sales ratio and EV/EBITDA are N/A or -0.36 respectively, suggesting that alternative valuation metrics relying on positive earnings or sales are not currently viable, with the EV/EBITDA of -0.36 reflecting the significant negative earnings before interest, taxes, depreciation, and amortization relative to enterprise value. The 52-week trading range spans from a low of $2.20 to a high of $14.21, providing a context for price volatility and historical trading bounds without specifying the exact current price. The beta value is 2.76, which means the stock exhibits high price volatility relative to the broader market, moving with significantly greater magnitude than the S&P 500 and amplifying both potential gains and losses during market swings.
Growth & Income
Revenue growth and earnings growth year-over-year are listed as N/A, as the company has not yet achieved commercial sales to establish a baseline for growth calculations. Consequently, it is impossible to determine if earnings are growing faster or slower than revenue because both metrics are currently non-existent, placing the company in a pre-growth phase where traditional growth rates do not apply. LeonaBio, Inc. does not pay dividends, with a dividend yield of N/A and a payout ratio of 0.0%, indicating that the company reinvests all available resources, including its cash balance, into research, development, and clinical operations rather than distributing income to shareholders. The overall growth and income profile is defined by a total reliance on capital markets to fund operations in the absence of dividend income or established revenue growth, positioning the asset as a pure speculative play on future therapeutic approvals rather than a source of current yield or growth.